The Newswire

Your daily serving of financial goodness

Virtus Health Revises Earnings Forecast

Virtus Health Revises Earnings Forecast
Jun 02, 2015 By Simon Herrmann

Health care provider Virtus Health (ASX:VRT) has revised its earnings guidance on Tuesday. The report released to the ASX said the earnings forecast was changed due to current trading activity and lower than forecasted cycles. In February, the company said its guidance would meet net profit after tax (NPAT) growth in the low to mid-teens before non-recurring items. The company’s profit guidance has been revised down to low to mid-single digit percentage growth in NPAT before non-recurring items.

Virtus listed 4 key factors for the lowered earnings forecast. NSW cycle growth was cited as being insufficient to reach previous growth levels. Although the company has experienced 6 per cent growth in the NSW market in the three months to April, the growth is attributable to bulk bill providers rather than true growth. The Maroubra Clinic suffered storm damage, which also resulted in lower earnings. The storm caused cycle volumes to decrease and it is not expected to return to previous levels until August 2015. Cycle volumes in Singapore Clinics have also been lower than anticipated. In Victoria and Queensland, Virtus has lost a small percentage of market share.

Australia’s largest IVF provider changed its non-recurring items from $2.1m to $2.3m in the report on Tuesday. Analysts have noted that the lowered growth may be due to market cycles. Morgan Stanley economists believe the IVF growth cycle is returning to previous levels. However, Virtus has also lost market share in addition to suffering from slower growth cycles. Shares of Virtus are down $1.29, or 16.91 per cent, at $6.34 per cent around 1:29pm on Tuesday. VRT has fallen 25.82 per cent in the last 12 months and 19.11 per cent so far this year.

Share this article

Simon Herrmann Author: Simon Herrmann Jun 02, 2015

Simon is a financial analyst at independent research firm Wise-owl who wants to change the world by disrupting the cliché approach to investment decision making with convergent thinking. Wise-owl’s goal is plain and simple: Find the best opportunities for our members by following a proven methodology and to create long-term value through high-quality advice, innovation, technology and education. We combine industry experience and the agile mentality of a start-up. Wise-owl is the future of stock market investing.

Growing Cases of Cancer Fuel Demand for Diagnostic Technology: Sienna Cancer IPO

The Australian government estimates that over 130,000 new cancer cases will be diagnosed in 2017 and the risk of individuals dying from cancer by their 85th birthday will be one in five.

Author: Simon Herrmann Jun 23, 2017


Sign Up for Free Trial
Recent Tweets
Recent News